EyePoint EYPT 深 滬
等待開盤 08-21 09:30:00 美东时间
5.40
-0.900
-14.29%
華盛通- 最 高6.29
- 今 開6.18
- 成交量 740.57万股
- 最 低 5.295
- 昨 收 6.30
- 總市值 4.66亿
- 52周最高 19.11
- 市盈率 靜 --
- 換手率 8.59%
- 52周最低 3.95
- 委 比 38.96%
- 總股本 8621.21万
- 歷史最高 39.40
- 量 比 0.46
- 振 幅 15.79%
- 歷史最低 2.19
- 每 手 1
- 風險率 1.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多A股盘前市场要闻速递（2026-08-19）
小程序：A股盘前市场要闻速递 重要新闻 1. 重大突破，我国首次实现火箭陆地回收 今天（8月19日），朱雀三号遥二运载火箭在东风商业航天创新试验区发射升空，火箭...
08-19 09:02
These Analysts Slash Their Forecasts On EyePoint
EyePoint Inc. (NASDAQ:EYPT) on Monday released topline results from its pivotal Phase 3 LUGANO clinical trial evaluating DURAVYU for the treatment of wet age-related macular degeneration. While key secondary endpoints showed significant clinical progress, the study failed to meet its primary visual ...
08-19 00:11
EyePoint rebounds after selloff despite multiple downgrades
After losing more than 65% in the previous session following a late-stage trial setback for its lead asset, Duravyu, EyePoint added 7% in morning trading despite facing multiple downgrades on Wall Str...
08-18 22:17
贝达药业(300558.SZ)：合作伙伴公布DURAVYU治疗湿性年龄相关性黄斑变性开展的两项关键Ⅲ期临床试验中的首项试验数据
格隆汇8月18日丨贝达药业(300558.SZ)公布，公 司 合作伙伴EyePointPharmaceuticals, Inc.（NASDAQ：EYPT，简称...
08-18 20:48
贝达药业：合作伙伴公布DURAVYU治疗wAMD关键III期试验未达主要终点
8月18日，贝达药业（300558.SZ）公告，合作伙伴EyePoint公布DURAVYU治疗湿性年龄相关性黄斑变性(wAMD)的两项关键III期临床试验中首项...
08-18 20:40
EyePoint伏罗尼布wAMD三期临床不及预期股价大跌67%，贝达药业20CM跌停
8月18日，贝达药业（300558.SZ）20CM跌停，消息面上，EyePoint（EYPT.US）美股隔夜大跌67%，伏罗尼布wAMD三期临床不及预期，贝达药...
08-18 11:50
受伏罗尼布临床失败拖累 贝达药业20cm跌停 跌幅居市场首位
8月18日，贝达药业（300558.SZ）封跌停板，完全抹平此前涨幅，且跌幅居市场首位，报55.72元，总市值235.88亿元。 消息面上，8月17日，Eye...
08-18 11:46
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT). EyePoint released topline results from its pivotal Phase 3 LUGANO trial. The study evaluated Duravyu for wet age-related macular degeneration...
08-18 01:48
JP Morgan Downgrades EyePoint to Neutral
JP Morgan analyst Tessa Romero downgrades EyePoint (NASDAQ:EYPT) from Overweight to Neutral.
08-18 01:10
